HARMONIA seeks to identify the best therapeutic option between Kisqali and Ibrance ® for patients with aggressive HER2-enriched intrinsic subtype of HR+/HER2- advanced breast cancer (ABC)
PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) said that it has partnered with academic cooperative groups to initiate a pivotal trial of an oral selective estrogen receptor degrader or SERD in the adjuvant
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and.